$1.0M
1 filing since 2024 · latest Equity filed
TellBio is an Andover, Massachusetts biotechnology company working on circulating tumor cells (CTCs), the cancer cells that break off a tumor and travel in the bloodstream. Its diagnostics platform uses microfluidics to isolate viable CTCs from a blood draw regardless of the primary tumor type, and is deployed as a research tool at medical centers internationally. A separate therapeutics program develops anti-cancer drug candidates from what the CTC work reveals about metastasis. The underlying technology is exclusively licensed from Massachusetts General Hospital, and several MGH researchers are company founders.
What sets it apart
Isolates living, intact circulating tumor cells rather than fragments or cell-free DNA, and does so independently of tumor type, which supports both monitoring of metastatic progression and downstream functional testing of therapy response.
A microfluidic diagnostics platform that isolates circulating tumor cells from patient blood samples, currently in use as a research tool at medical centers worldwide.
